Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atazanavir Sulphate+ Ritonavir · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| C | ACTIVE_COMPARATOR | - |
| D | ACTIVE_COMPARATOR | - |
| E | ACTIVE_COMPARATOR | - |
| A1 | ACTIVE_COMPARATOR | - |
| A2 | ACTIVE_COMPARATOR | - |
| A3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Rosiglitazone maleate | DRUG | Tablets, Oral, RGZ 4 mg, once daily, 1 day. |
| Atazanavir Sulphate | DRUG | Capsules, Oral, ATV 400 mg, once daily, 5 days. |
| Atazanavir Sulphate + Rosiglitazone maleate | DRUG | Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day. |
| Atazanavir Sulphate + Ritonavir | DRUG | Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days. |
| Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate | DRUG | Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day. |
| Atazanavir Sulphate + Ritonavir + Efavirenz | DRUG | Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days. |
Inclusion Criteria: * Healthy male and female subjects between the ages 18 to 50 years old with a BMI 18 to 32 kg/m2
Top 20 of 28 competitors
Atazanavir Sulphate is an investigational small molecule being developed for the treatment of HIV and HIV Infections. It is currently in Phase 3 clinical development. The drug is being studied in combination with other antiretroviral agents, such as ritonavir, to manage HIV infection in affected patients.
Atazanavir Sulphate is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating HIV infections, with the most advanced study being a Phase 3 trial.
Atazanavir Sulphate is in Phase 3 clinical development for the treatment of HIV. The most advanced trial is a Phase 3 study evaluating the drug's effects in HIV-infected pediatric patients. This trial has been completed, and the drug remains investigational, not yet approved by regulatory authorities.
Atazanavir Sulphate has been studied in three completed clinical trials. These include NCT00357188 and NCT00357721, both Phase 1 studies in healthy subjects, and NCT01335698, a Phase 3 study in HIV-infected pediatric patients. The Phase 3 trial enrolled 160 participants across multiple countries.
Atazanavir Sulphate is a protease inhibitor used in the treatment of HIV. It works by inhibiting the HIV protease enzyme, which is essential for the virus to replicate. By blocking this enzyme, the drug prevents the virus from maturing and infecting new cells, thereby reducing viral load in patients.